Updates
** Shares of drugmaker Amgen AMGN.O gain 5.54% to $305.04, reversing premarket losses
** Co on Tuesday reported Q4 profit of $5.31 per share, beating estimates of $5.08 - LSEG data
** Said late-stage studies of key obesity drug candidate MariTide will start before mid-year
** However, U.S. FDA has placed clinical hold on early-stage trial of experimental weight-loss drug AMG 513
** AMGN does not believe issue leading to the hold is drug-related
** Obesity will continue to be key theme for Amgen shares as we enter 2025, brokerage BMO Capital Markets says
** Up to last close, stock down ~10% in last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.